2010年和2015年江西省恶性肿瘤疾病负担研究

The burden of cancers in Jiangxi Province,2010 and 2015

目的分析比较2010年和2015年江西省恶性肿瘤的疾病负担。方法从2015年中国分省份疾病负担研究中选取江西省恶性肿瘤的发病数、死亡数、过早死亡损失寿命年(years of life lost,YLL)、伤残损失寿命年(years lived with disability,YLD)和伤残调整寿命年(disability-adjusted life year,DALY)等数据资料,使用2010年全国人口普查数据作为标准人口,计算标化发病率、死亡率、YLL率、YLD率和DALY率,以此评价该省恶性肿瘤疾病负担的变化情况。结果 2015年江西省恶性肿瘤的总体发病数、死亡数、YLL、YLD和DALY高于2010年,且男性>女性,但标化发病率下降了3.25%、标化死亡率下降了8.42%、标化DALY率下降了8.64%。2010年和2015年,YLL/DALY为97.78%和97.58%;2010年和2015年,≥50岁人群标化DALY率分别占总体的88.19%和88.14%;2010年和2015年标化DALY率前五位的恶性肿瘤均为肺癌、肝癌、胃癌、结直肠癌和白血病。结论江西省2015年的恶性肿瘤疾病负担相比2010年有所下降但仍维持在较高水平,应重点做好男性和≥50岁人群肺癌、肝癌、胃癌、结直肠癌和白血病的防治工作。

Objective To analyze and compare the burden of cancers in Jiangxi Province,2010 and 2015. Methods We selected the data of cancers in Jiangxi Province from the global burden of disease 2015 in China which included incidence,death,years of life lost（ YLL）,years lived with disability（ YLD）,and disability adjusted of life years（ DALY）. Then the standardized incidence rate,mortality rate,YLL rate,YLD rate and DALY rate were calculated with the2010 national census data to assess the trend of cancers in Jiangxi Province. Results The incidence,death,YLL,YLD and DALY of cancers in Jiangxi Province in 2015 were higher than that of 2010,and males were higher than females. However,the corresponding standardized incidence rate,mortality rate and DALY rate decreased by 3. 25%,8. 42% and8. 64% when compared with that in 2010. In 2010 and 2015,the proportion of YLL/DALY were 97. 78% and 97. 58%,and the standardized DALY rate of people aged 50 and over accounted for 88. 19% and 88. 14% of the total. Besides,the top five standardized DALY rate of cancers both were lung cancer,liver cancer,gastric cancer,colorectal cancer and leukemia in 2010 and 2015. Conclusions The burden of cancers in Jiangxi Province in 2015 decreased when compared with that in 2010,but it remained at high levels. Prevention and control should be given in priority to lung cancer,liver cancer,gastric cancer,colorectal cancer and leukemia in males and people aged 50 and over.